Novartis gains EC approval of Cosentyx for polymyalgia rheumatica (NVS:NYSE)

Novartis announced that the European Commission approved its drug Cosentyx for treating polymyalgia rheumatica. This expands the drug's approved uses. Novartis is a Swiss multinational pharmaceutical company.

Novartis (NVS) received European Commission approval for Cosentyx to treat polymyalgia rheumatica. The company offers a 3.07% dividend yield, a 43% payout ratio, and a 5% 3-year dividend growth rate. Novartis has a GF Score of 71, indicating solid fundamentals but weaker momentum. Institutional interest is mixed, with 10 gurus trimming positions and 6 adding.

The European Commission has approved Novartis' drug Cosentyx for treating polymyalgia rheumatica. Novartis' stock is currently trading at 127.06 CHF, up 0.44% on the day and 3.38% over the past year. This approval expands the drug's approved uses and may impact Novartis' revenue.

Novartis (NVS) received European Commission approval for its drug Cosentyx to treat polymyalgia rheumatica (PMR). The approval expands the drug's indications. Novartis' stock is up 3.36% year-to-date.

Novartis (NOT) received European Commission approval for Cosentyx (secukinumab) to treat adults with polymyalgia rheumatica (PMR) who inadequately respond to glucocorticoids. The approval, based on the Phase III REPLENISH trial, makes Cosentyx the first IL-17A inhibitor approved in Europe for this indication. Additional regulatory reviews are ongoing in the US and Japan.

FDA approved Biofrontera's Ameluz for superficial basal cell carcinoma, showing 66% efficacy in trials. Regeneron's cemiplimab and Novartis' remibrutinib also gained approvals for skin cancer and dermographism. Dermatologist Todd Schlesinger discussed these advancements and ongoing research at a conference.